Molecular Property Diagnostic Suite for COVID-19 (MPDSCOVID-19): An open access disease specific drug discovery portal
Lipsa PriyadarsineeiD, Esther JamiriD, Selvaraman NagamaniiD, Hridoy Jyoti MahantaiD, Nandan KumariD, Lijo JohniD, Himakshi SarmaiD, Asheesh KumariD, Anamika Singh GauriD, Rosaleen Sahoo, S. VaikundamaniiD, N. Arul MuruganiD, U. Deva PriyakumariD, Gajendra P. S. RaghavaiD, Prasad V. BharatamiD, Ramakrishnan ParthasarathiiD, Venkatachalam SubramanianiD, G. Madhavi Sastry, G. Narahari SastryiD
Abstract
Computational drug discovery is intrinsically interdisciplinary and has to deal with the multifarious factors which are often dependent on the type of disease. Molecular Property Diagnostic Suite (MPDS) is a Galaxy based web portal which was conceived and developed as a disease specific web portal, originally developed for tuberculosis (MPDSTB). As specific computational tools are often required for a given disease, developing a disease specific web portal is highly desirable. This paper emphasises on the development of the customised web portal for COVID-19 infection and is referred to as MPDSCOVID-19. Expectedly, the MPDS suites of programs have modules which are essentially independent of a given disease, whereas some modules are specific to a particular disease. In the MPDSCOVID-19 portal, there are modules which are specific to COVID-19, and these are clubbed in SARS-COV-2 disease library. Further, the new additions and/or significant improvements were made to the disease independent modules, besides the addition of tools from galaxy toolshed. This manuscript provides a latest update on the disease independent modules of MPDS after almost 6 years, as well as provide the contemporary information and tool-shed necessary to engage in the drug discovery research of COVID-19. The disease independent modules include file format converter and descriptor calculation under the data processing module; QSAR, pharmacophore, scaffold analysis, active site analysis, docking, screening, drug repurposing tool, virtual screening, visualisation, sequence alignment, phylogenetic analysis under the data analysis module; and various machine learning packages, algorithms and in-house developed machine learning antiviral prediction model are available. The MPDS suite of programs are expected to bring a paradigm shift in computational drug discovery, especially in the academic community, guided through a transparent and open innovation approach. The MPDSCOVID-19 can be accessed at http://mpds.neist.res.in:8085.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
Luca Menestrina, Chiara Cabrelle, Maurizio Recanatini·Scientific ReportsPeer-reviewed·Sep 30, 2021
- COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms
Marek Ostaszewski, Anna Niarakis, … Özgün Babur·Molecular Systems BiologyPeer-reviewed·Oct 1, 2021
- DRDOCK: A Drug Repurposing platform integrating automated docking, simulations and a log-odds-based drug ranking scheme
Kun-Lin Tsai, Sui‐Yuan Chang, Lee‐Wei Yang·bioRxiv·Jan 31, 2021
- A versatile and interoperable computational framework for the analysis and modeling of COVID-19 disease mechanisms
Anna Niarakis, Marek Ostaszewski, … the COVID-19 Disease Map Community·bioRxiv·Dec 17, 2022
- Machine Learning Models Identify Inhibitors of SARS-CoV-2
V. O. Gawriljuk, P. P. Kyaw Zin, … S. Ekins·bioRxiv·Jun 16, 2020
- Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research
K. R. Brimacombe, P. C. Scully, … M. D. Hall·bioRxiv·Jun 4, 2020